Companies / EYE

NOVA EYE MEDICAL LIMITED

ASX:EYEHealth Care Equipment & Services
284.9M shares on issueASX (delayed) · as of 28 July 2026$0.13price · delayed$35.6Mmarket cap · indicative
C
Dilution grade

Runway under 2 quarters; share count grew 24% in 24 months; 1 cash raise in 24 months

Cash runway-0.3 quarters of funding
Share-count growth (24m)24.5%
Raise cadence (24m)1 cash raise
Options & rights overhang0.0% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

NOVA EYE MEDICAL LIMITED's ordinary share count grew 24.5% between May 2024 and July 2026, to 285M shares. The company raised capital once in the 24-month window for total proceeds of A$6.6M, most recently in January 2025 for A$6.6M. Options and rights could convert into 49,000 new shares, equal to 0.0% of the current share count, with 0% in the money. At the March 2026 quarter the company reported A$-317K in available cash, equal to -0.3 quarters of cover. There are no proposed securities issues (Appendix 3B) pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
0.0%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
-0.3 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 284.9M per ASX (delayed) (28 July 2026).
240.8M257.0M273.2MDec 24Sept 25July 26Cash raise · 31 Jan 2025

Cash runway

-0.3 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$-317k available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
10 July 20262A · quoted issueEYE : ORDINARY FULLY PAID284.9MAppendix 2A
25 June 20263H · cancellationEYE : ORDINARY FULLY PAID284.9MAppendix 3H
25 June 20263H · cancellationEYE : ORDINARY FULLY PAID284.9MAppendix 3H
6 May 20263G · unquotedEYE : ORDINARY FULLY PAID284.8MAppendix 3G
6 May 20262A · quoted issueEYE : ORDINARY FULLY PAID284.9MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

1 cash raise in the last 24 months · 0 in the last 12 months

$6.6M
Capital raise
31 Jan 2025
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

0.0%
Total overhang · of current shares
0.0%
In the money · at current price
49k
Potential new shares
—
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
1 Sept 2025Thomas Anthony SpurlingBuy78k——3Y notice
4 Aug 2025Thomas Anthony SpurlingOther300k——3Y notice
26 Mar 2025Daniel WebbBuy417k——3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

10 July 2026Application for quotation of securities - EYE
25 June 2026Notification of cessation of securities - EYE
25 June 2026Notification of cessation of securities - EYE
6 May 2026Notification regarding unquoted securities - EYE
6 May 2026Application for quotation of securities - EYE
4 May 2026$PEYE lifts Sales Guidance
4 May 2026Q3FY26 Investor Presentation May26
30 Apr 2026Investor Webinar Tuesday 5 May @ 11.30 AEST
28 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
10 Mar 2026Application for quotation of securities - EYE
2 Mar 2026EYE Receives EU MDR Certification
25 Feb 2026Investor Webinar Tuesday 3 March @11.30 AEDT
25 Feb 2026Investor Presentation Half Year Results
25 Feb 2026$PEYE Delivers Sales Growth and Improves Bottom Line
25 Feb 2026$PHalf Yearly Report and Accounts
11 Feb 2026Re-lodgement of Appendix 4G
4 Feb 2026Peer-Reviewed Real-World Evidence Supports iTrack
29 Jan 2026Investor Webinar Monday 2 February @ 11.30 AEDT
28 Jan 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
26 Jan 2026ITrack Registry Clinical Data Update

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.